Utility of modified Glasgow prognostic score for head and neck squamous cell carcinoma: Systematic review and meta‐analysis
Chih‐Wei Luan, Liang‐Tseng Kuo, Yunting Wang, Chun‐Ta Liao, Chung‐Jan Kang, Yi‐Chan Lee, K.-C. Chen, Chia‐Hsuan Lai, Yuan‐Hsiung Tsai, Yuan‐Hsiung Tsai, Ethan I. Huang, Ming‐Shao Tsai, Cheng‐Ming Hsu, Geng‐He Chang, Yao‐Te Tsai, Yao‐Te Tsai
Abstract
Whether the modified Glasgow prognostic score (mGPS) is useful for patients with head and neck squamous cell carcinoma (HNSCC) remains controversial. An electronic database search on EMBASE, PubMed, and the Cochrane Library from inception to 30 June 2022 was performed for study selection and data extraction. The associations between the mGPS and survival outcomes were evaluated using a random-effects meta-analysis and expressed as pooled hazard ratios (HRs) and 95% CIs. We included 11 studies involving a total of 2017 patients with HNSCC. A higher mGPS was associated with poorer progression-free survival (HR = 2.39, 95% CI 1.69-3.38), overall survival (HR = 2.40, 95% CI 1.94-2.98), disease-specific survival (HR = 2.57, 95% CI 1.71-3.88), and disease-free survival (HR = 2.67, 95% CI 1.51-4.73, all p ≤ 0.001) in HNSCC. The mGPS can function as a valid prognostic biomarker for patients diagnosed as having HNSCC.